Enhertu: Mechanism of Action and Clinical Outcomes in Advanced Breast Cancer

Enhertu (fam-trastuzumab deruxtecan-nxki) is a promising drug in the field of cancer treatment, particularly for HER2-positive breast cancer. It is a tyrosine kinase inhibitor (TKI) that targets the HER2 protein, which plays a crucial role in the growth and development of cancer cells. Enhertu is being developed by Daiichi Sankyo and has shown promising results in clinical trials for its potential to improve outcomes for patients with advanced breast cancer.

How Enhertu Works

Enhertu (fam-trastuzumab deruxtecan-nxki) is a targeted treatment known as an antibody-drug conjugate (ADC) designed to work differently than traditional chemotherapies. It combines an antibody that targets the HER2 protein in cancer cells with a chemotherapy drug called deruxtecan. 

When the antibody attaches to the HER2 protein, it delivers deruxtecan directly into the breast cancer cells to kill them. Additionally, Enhertu has a ‘bystander effect’, meaning it also kills any neighboring cancer cells, even if they do not have a higher level of HER2 on their surface.

Impact on Advanced Breast Cancer

Clinical trials have shown that Enhertu, in combination with other drugs, has demonstrated promising results in the treatment of HER2-positive advanced breast cancer. Some key findings from these trials include:

• Improvement in progression-free survival (PFS), overall survival (OS), and objective response rate (ORR)
• Significant reduction in the risk of disease progression or death compared to placebo
• Manageable safety profile, with common side effects such as diarrhea, fatigue, and gastrointestinal symptoms. 
• The future of Enhertu in cancer treatment is expected to grow as more research and clinical trials are conducted to determine the optimal use of Enhertu in clinical practice

These results indicate that Enhertu, when used in combination with other drugs, has the potential to significantly impact the treatment of advanced HER2-positive breast cancer. 

For those seeking to buy Enhertu online, exclusively available in the US and Europe, Sansfro Health offers a trustworthy solution. Committed to streamlining the importation process, Sansfro Health provides precise pricing details for a smooth experience. Sansfro facilitates the importation with authentic pricing and comprehensive assistance.

Individuals interested in importing medication must provide a valid prescription, identity proof, healthcare professional details, and current address. The Sansfro team initiates the import license application, ensuring access to the necessary medication upon government approval. For inquiries about the Enhertu price in India and to understand the importation procedure, individuals can contact the Patient Support Team at (+91) 93157 05373 or via email at help@sansfro.com. 

Reference

1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761139s021lbl.pdf 
2. https://www.drugs.com/enhertu.html 
3. https://www.breastcancer.org/treatment/targeted-therapy/enhertu
4. https://www.enhertu.com/en/her2-low-breast/about-enhertu-and-dosing
5. https://www.cancer.gov/news-events/cancer-currents-blog/2022/enhertu-her2-low-breast-cancer